The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1745
ISSUE1745
Med Lett Drugs Ther. 2026 Jan 5;68(1745):8 doi:10.58347/tml.2026.1745e
Disclosures
Objective(s)
In our recent article titled Expanded Indication for PCSK9 Inhibitors (Med Lett Drugs Ther 2025; 67:201), the number needed to treat (NNT) to prevent one composite endpoint of myocardial infarction, ischemic stroke, or death from coronary heart disease in the VESALIUS-CV trial was incorrectly stated as 5 instead of 56.
© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and
complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any
damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
Previous article